NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. - Zheng ZY; Chen A; Jaehnig EJ; Anurag M; Lei JT; Feng L; Wang C; Fandino D; Singh P; Kennedy H; Yadav G; Vollert CT; et al. (Science translational medicine, 2025)